Search

Your search keyword '"Borghi, V"' showing total 533 results
Start Over Author "Borghi, V"
533 results on '"Borghi, V"'

102. Virological response and resistance profile in HIV-1-infected patients starting darunavir-containing regimens

Author

Armenia, D, primary, Di Carlo, D, additional, Maffongelli, G, additional, Borghi, V, additional, Alteri, C, additional, Forbici, F, additional, Bertoli, A, additional, Gori, C, additional, Giuliani, M, additional, Nicastri, E, additional, Zaccarelli, M, additional, Pinnetti, C, additional, Cicalini, S, additional, D'Offizi, G, additional, Ceccherini-Silberstein, F, additional, Mussini, C, additional, Antinori, A, additional, Andreoni, M, additional, Perno, CF, additional, and Santoro, MM, additional

Published
2016
Full Text
View/download PDF

106. Evolution of transmitted HIV‐1 drug resistance and viral subtypes circulation in Italy from 2006 to 2016.

Author

Rossetti, B., Di Giambenedetto, S., Torti, C., Postorino, M. C., Punzi, G., Saladini, F., Gennari, W., Borghi, V., Monno, L., Pignataro, A. R., Polilli, E., Colafigli, M., Poggi, A., Tini, S., Zazzi, M., De Luca, A., and the Antiviral Response Cohort Analysis (ARCA) Collaborative Group

Subjects
HIV infection genetics, THERAPEUTIC use of protease inhibitors, ANTIRETROVIRAL agents, NON-nucleoside reverse transcriptase inhibitors, NUCLEOSIDE reverse transcriptase inhibitors, HIV infection epidemiology, HIV integrase inhibitors, CONFIDENCE intervals, DATABASES, DRUG resistance, HIV, HIV infections, MEDICAL information storage & retrieval systems, LONGITUDINAL method, GENETIC mutation, PROBABILITY theory, PUBLIC health surveillance, VIRAL load, ODDS ratio, THERAPEUTICS
Abstract

Objectives: The aim was to evaluate the evolution of transmitted HIV‐1 drug resistance (TDR) prevalence in antiretroviral therapy (ART)‐naïve patients from 2006 to 2016. Methods: HIV‐1 sequences were retrieved from the Antiviral Response Cohort Analysis (ARCA) database and TDR was defined as detection of at least one mutation from the World Health Organization (WHO) surveillance list. Results: We included protease/reverse transcriptase sequences from 3573 patients; 455 had also integrase sequences. Overall, 68.1% of the patients were Italian, the median CD4 count was 348 cells/μL [interquartile range (IQR) 169–521 cells/μL], and the median viral load was 4.7 log10 HIV‐1 RNA copies/mL (IQR 4.1–5.3 log10 copies/mL). TDR was detected in 10.3% of patients: 6% carried mutations to nucleos(t)ide reverse transcriptase inhibitors (NRTIs), 4.4% to nonnucleos(t)ide reverse transcriptase inhibitors (NNRTIs), 2.3% to protease inhibitors (PIs), 0.2% to integrase strand transfer inhibitors (INSTIs) and 2.1% to at least two drug classes. TDR declined from 14.5% in 2006 to 7.3% in 2016 (P = 0.003): TDR to NRTIs from 9.9 to 2.9% (P = 0.003) and TDR to NNRTIs from 5.1 to 3.7% (P = 0.028); PI TDR remained stable. The proportion carrying subtype B virus declined from 76.5 to 50% (P < 0.001). The prevalence of TDR was higher in subtype B vs. non‐B (12.6 vs. 4.9%, respectively; P < 0.001) and declined significantly in subtype B (from 17.1 to 8.8%; P = 0.04) but not in non‐B subtypes (from 6.1 to 5.8%; P = 0.44). Adjusting for country of origin, predictors of TDR were subtype B [adjusted odds ratio (AOR) for subtype B vs. non‐B 2.91; 95% confidence interval (CI) 1.93–4.39; P < 0.001], lower viral load (per log10 higher: AOR 0.86; 95% CI 0.75–0.99; P = 0.03), site in northern Italy (AOR for southern Italy/island vs. northern Italy, 0.61; 95% CI 0.40–0.91; P = 0.01), and earlier calendar year (per 1 year more recent: AOR 0.95; 95% CI 0.91–0.99; P = 0.02). Conclusions: The prevalence of HIV‐1 TDR has declined during the last 10 years in Italy. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

107. Impact of transmitted HIV-1 drug resistance on the efficacy of first-line antiretroviral therapy with two nucleos(t)ide reverse transcriptase inhibitors plus an integrase inhibitor or a protease inhibitor.

Author

Raffaelli, C Spertilli, Rossetti, B, Paglicci, L, Colafigli, M, Punzi, G, Borghi, V, Pecorari, M, Santoro, M M, Penco, G, Antinori, A, Spertilli Raffaelli, C, Zazzi, M, De Luca, A, and Zanelli, G

Subjects
DRUG resistance, ANTIRETROVIRAL agents, DRUG efficacy, HIV infections, GENOTYPES
Abstract

Objectives: To examine the impact of transmitted drug resistance (TDR) on response to first-line regimens with integrase strand transfer inhibitors (INSTIs) or boosted protease inhibitors (bPIs).Methods: From an Italian observational database (ARCA) we selected HIV-1-infected drug-naive patients starting two NRTIs and either an INSTI or a bPI, with an available pre-ART resistance genotype. The endpoint was virological failure (VF; plasma HIV-1 RNA >200 copies/mL after week 24). WHO surveillance drug resistance mutations and the Stanford algorithm were used to classify patients into three resistance categories: no TDR (A), TDR but fully-active ART prescribed (B), TDR and at least low-level resistance to one or more prescribed drug (C).Results: We included 1365 patients with a median follow-up of 96 weeks (IQR 54-110): 1205 (88.3%) starting bPI and 160 (11.7%) INSTI. Prevalence of TDR was 6.1%, 12.5%, 2.6% and 0% for NRTI, NNRTI, bPI and INSTI, respectively. Cumulative Kaplan-Meier estimates for VF at 48 weeks were 11% (95% CI 10.1%-11.9%) for the bPI group and 7.7% (95% CI 5.4%-10%) for the INSTI group. In the INSTI group, cumulative estimates for VF at 48 weeks were 6% (95% CI 4%-8%) in resistance category A, 5% (95% CI 1%-10%) in B and 50% (95% CI 30%-70%) in C (P < 0.001). Resistance category C [versus A, adjusted hazard ratio (aHR) 12.6, 95% CI 3.2-49.8, P < 0.001] and nadir CD4 (+100 cells/mm3, aHR 0.6, 95% CI 0.4-0.9, P = 0.03) predicted VF. In the bPI group, VF rates were not influenced by baseline resistance.Conclusions: Our data support the need for NRTI resistance genotyping in patients starting an INSTI-based first-line ART. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

109. A novel methodology for large-scale phylogeny partition

Author

Prosperi, Mc, Ciccozzi, M, Fanti, I, Saladini, F, Pecorari, M, Borghi, V, Di Giambenedetto, S, Bruzzone, B, Capetti, A, Vivarelli, A, Rusconi, S, Re, Mc, Gismondo, Mr, Sighinolfi, L, Gray, Rr, Salemi, M, Zazzi, M, De Luca, A, CollaboratorsGiacometti A, ARCA collaborative g. r. o. u. p., Butini, L, Menzo, S, Tacconi, D, Corbelli, G, Zanussi, S, Monno, L, Punzi, G, Maggiolo, F, Callegaro, A, Calza, L, Pristerà, R, Turconi, P, Mandas, A, Tini, S, Zoncada, A, Paolini, E, Amadio, G, Zuccati, G, Morfini, M, Manetti, R, Corsi, P, Galli, L, Di Pietro, M, Bartalesi, F, Colao, G, Tosti, A, Di Biagio, A, Setti, M, Penco, G, Trezzi, M, Orani, A, Pardelli, R, De Gennaro, M, Chiodera, A, Scalzini, A, Palvarini, L, Almi, P, Todaro, G, Cicconi, P, Micheli, V, Biondi, Ml, Gianotti, N, Meraviglia, P, Boeri, E, Mussini, C, Soria, A, Vecchi, L, Santirocchi, M, Brustia, D, Ravanini, P, Dal Bello, F, Romano, N, Mancuso, S, Calzetti, C, Maserati, R, Filice, G, Baldanti, F, Francisci, D, Parruti, G, Polilli, E, Sacchini, D, Martinelli, C, and Consolini, Rita

Published
2011

110. Long-term CD4+ T-cell count evolution after switching from regimens including HIV nucleoside reverse transcriptase inhibitors (NRTI) plus protease inhibitors to regimens containing NRTI plus non-NRTI or only NRTI

Author

Torti, Carlo, d'Arminio Monforte, A, Pozniak, Al, Lapadula, G, Cologni, G, Antinori, A, De Luca, A, Mussini, C, Castagna, A, Cicconi, P, Minoli, L, Costantini, A, Carosi, Giampiero, Liang, H, Cesana, Bm, Master, Chelsea, Westminster, Icona, Modena, Collaborators: Carosi G, S. Raffaele HIV C. o. h. o. r. t. s., Puoti, M, Torti, C, QUIROS ROLDAN, Maria Eugenia, Paraninfo, G, Casari, S, Pastore, G, Ladisa, N, Suter, F, Maggiolo, F, Quirino, T, Migliorino, M, Ghinelli, F, Sighinolfi, L, Mazzotta, F, Lo Caputo, S, Marino, N, Angarano, A, Saracino, A, D'Arminio Monforte, A, Maserati, R, Novati, S, Tinelli, C, Antonucci, G, Ammassari, A, Cauda, R, Montroni, M, Scalise, G, Braschi, Mc, Riva, A, Tirelli, U, Martellotta, F, Minafra, G, Arici, C, Chiodo, F, Colangeli, V, Fiorini, C, Coronado, O, Carosi, G, Cristini, G, Minardi, C, Bertelli, D, Melzi, S, Manconi, Pe, Piano, P, Cosco, L, Scerbo, A, Pizzigallo, E, D'Alessandro, M, Santoro, D, Pusterla, L, Carnevale, G, Zoncada, A, Viganò, P, Mena, M, Leoncini, F, Pozzi, M, Angarano, G, Grisorio, B, Ferrara, S, Grima, P, Tundo, P, Pagano, G, Cassola, G, Alessandrini, A, Piscopo, R, Toti, M, Trezzi, M, Soscia, F, Tacconi, L, Orani, A, Perini, P, Scasso, A, Vincenti, A, Chiodera, F, Castelli, P, Scalzini, A, Palvarini, L, Moroni, M, Lazzarin, A, Rizzardini, G, Caggese, L, Repetto, D, Galli, A, Merli, S, Pastecchia, C, Moioli, Mc, Esposito, R, Abrescia, N, Chirianni, A, Izzo, Cm, Piazza, M, De Marco, M, Viglietti, R, Manzillo, E, Nappa, S, Colomba, A, Abbadessa, V, Prestileo, T, Mancuso, S, Ferrari, C, Pizzaferri, P, Filice, G, Bruno, R, Baldelli, F, Camanni, G, Petrelli, E, Cioppi, A, Alberici, F, Ruggieri, A, Menichetti, F, Martinelli, C, De Stefano, C, La Gala, A, Ballardini, G, Rizzo, E, Magnani, G, Ursitti, Ma, Arlotti, M, Ortolani, P, Dianzani, F, Ippolito, G, Ciardi, M, Narciso, P, Petrosillo, N, Vullo, V, Zaccarelli, M, Acinapura, R, De Longis, P, Murri, R, Trotta, Mp, Noto, P, Lichtner, M, Capobianchi, Mr, Carletti, F, Perno, Cf, Girardi, E, Pezzotti, P, Rezza, G, Mura, Ms, Mannazzu, M, Caramello, P, Di Perri, G, Orofino, Gc, Sciandra, M, Grossi, Pa, Basilico, C, Poggio, A, Bottari, G, Raise, E, Ebo, F, Pellizzer, G, Buonfrate, D, Resta, F, Loso, K, Cozzi Lepri, A, Borghi, V, Galli, L, Sampietro, S, Mandalia, S, and Gazzard, B.

Published
2011

112. Death rates in HIV-positive antiretroviral-naive patients with CD4 count greater than 350 cells per microL in Europe and North America: a pooled cohort observational study

Author

Study Group on Death Rates at High CD4 Count in Antiretroviral Naive Patients, Lodwick, Rk, Sabin, Ca, Porter, K, Ledergerber, B, van Sighem, A, Cozzi Lepri, A, Khaykin, P, Mocroft, A, Jacobson, L, De Wit, S, Obel, N, Castagna, A, Wasmuth, Jc, Gill, J, Klein, Mb, Gange, S, Riera, M, Mussini, C, Gutiérrez, F, Touloumi, G, Carrieri, P, Guest, Jl, Brockmeyer, Nh, Collaborators: Antoniadou A, Phillips A. N., Gargalianos Kakolyris, P, Katsarou, O, Kordossis, T, Lazanas, M, Panos, G, Paparizos, V, Paraskevis, D, Petrikkos, G, Sambatakou, H, Skoutelis, A, Pantazis, N, Bakoyannis, G, Gioukari, V, de Wolf, F, Bezemer, Do, Gras, La, Kesselring, Am, van Sighem AI, Smit, C, Zhang, S, Zaheri, S, Prins, Jm, Schreij, G, Bravenboer, B, van der Ende ME, Kauffmann, Rh, ten Kate RW, Kroon, Fp, Bronsveld, W, Vriesendorp, R, van Houte, D, ten Napel CH, Brinkman, K, van Eeden, A, Mulder, Jw, Juttmann, Jr, Veenstra, J, Koopmans, Pp, Sprenger, Hg, Hoepelman, Im, Danner, Sa, Richter, C, Tanis, Aa, Clumeck, N, Delforge, M, Necsoi, C, Demeester, R, Gennotte, Af, Gerard, M, Guillaume, Mp, Hermans, P, Kabeya, K, Konopnicki, D, Martin, C, Libois, A, Payen, Mc, Semaille, P, Van Laethem, Y, Del Amo, J, Meyer, L, Bucher, Hc, Chêne, G, Pillay, D, Prins, M, Rosinska, M, Sabin, C, Lodi, S, Coughlin, K, Walker, S, Babiker, A, Bucher, H, de Luca, A, Fisher, M, Muga, R, Fätkenheuer, G, Rockstroh, J, Vehreschild, J, Hertenstein, C, Berenguer, J, del Amo, J, García, F, Labarga, P, Moreno, S, Angeles Muñoz, M, Caro Murillo AM, Sobrino, P, Pérez Cachafeiro, S, Jarrín, I, Alejos, B, García, I, Gómez Sirvent, J, Soriano, V, Pulido, F, Iribarren, J, Masiá, M, Vidal, F, Sanz, J, Blanco, Ja, Sola, J, Gerstoft, J, Kronborg, G, Røge, B, Larsen, Cs, Pedersen, G, Laursen, Al, Nielsen, L, Jensen, J, Babacan, E, Bickel, M, Bodtländer, A, Brodt, Hr, Carlebach, A, Gute, P, Haberl, A, Helm, E, Klauke, S, Knecht, G, Lennemann, T, Locher, L, Lutz, T, Mösch, M, Müller, A, Nisius, G, Staszewski, S, Stephan, C, Stürmer, M, von Hentig, N, Wolf, T, Rimland, D, Moanna, A, Moorfield, M, Dorsey, M, Desilva, Ke, Schlueter Wirtz, S, Mindley, R, Dozier, R, Robinson, Y, Brown, P, Moroni, M, Angarano, G, Antinori, A, Carosi, G, Cauda, R, d'Arminio Monforte, A, Di Perri, G, Galli, M, Ghinelli, G, Iardino, R, Ippolito, G, Lazzarin, A, Mazzotta, F, Perno, Cf, Viale, Pl, Von Schlosser, F, Ammassari, A, Balotta, C, Bonfanti, P, Capobianchi, Mr, Ceccherini Silberstein, F, De Luca, A, Gervasoni, C, Girardi, E, Lo Caputo, S, Maggiolo, F, Murri, R, Puoti, M, Torti, Carlo, Salpietro, S, Marangione, M, Galli, L, Gianotti, N, Cossarini, F, Spagnuolo, V, Arendt, G, Esser, S, Jäger, H, Schwarze, S, Stoll, M, Wolf, H, Jansen, K, Michalik, C, Skaletz Rorowski, A, Königs, C, Gingelmaier, A, Margolick, Jb, Jacobson, Lp, Phair, Jp, Wolinsky, Sm, Detels, R, Rinaldo, Cr, Boirot, C, Bouhnik, Ad, Carrieri, Mp, Cassuto, Jp, Chesney, M, Cohen, J, Dellamonica, P, Dujardin, P, Gallais, H, Gastaut, Ja, Kurkdji, P, Lepeu, G, Mechali, D, Moatti, Jp, Moreau, J, Nègre, M, Obadia, Y, Poizot Martin, I, Pradier, C, Préau, M, Rey, D, Roux, P, Rouzioux, C, Sobel, A, Spire, B, Trémolières, F, Villes, V, Vincent, E, Vlahov, D, Borghi, V, Casabona, J, Miró, Jm, Gatell, Jm, López Dieguez Puerta, M, Tural, C, Clotet, B, Podzamczer, D, Ferrer, E, Murillas, J, Segura, F, Navarro, G, Force, L, Vilaró, J, Masabeu, A, Guadarrama, M, Betancourt, Aj, Romero, A, Agustí, C, Battegay, M, Bernasconi, E, Böni, J, Bürgisser, P, Calmy, A, Cavassini, M, Dubs, R, Egger, M, Elzi, L, Fischer, M, Flepp, M, Fontana, A, Francioli, P, Furrer, H, Fux, Ca, Gorgievski, M, Günthard, Hf, Hirsch, Hh, Hirschel, B, Hösli, I, Kahlert, C, Kaiser, L, Karrer, U, Kind, C, Klimkait, T, Martinetti, G, Martinez, B, Müller, N, Nadal, D, Paccaud, F, Pantaleo, G, Rauch, A, Regenass, S, Rickenbach, M, Rudin, C, Schmid, P, Schultze, D, Schöni, F, Schüpbach, J, Speck, R, Taffé, P, Telenti, A, Trkola, A, Vernazza, P, Weber, R, Yerly, S, Ainsworth, J, Anderson, J, Delpech, V, Dunn, D, Easterbrook, P, Gazzard, B, Gilson, R, Gompels, M, Hill, T, Johnson, M, Leen, C, Nelson, M, Orkin, C, Palfreeman, A, Phillips, A, Post, F, Schwenk, A, Walsh, J, Bansi, L, Huntington, S, Glabay, A, Anastos, K, Minkoff, H, Young, M, Greenblatt, R, Levine, A, Cohen, M, and Gange, S.

Published
2010

113. Non-alcoholic Fatty Liver Disease: a HR-MAS analysis

Author

Filace, F., Righi, Valeria, Stentarelli, Chiara, Guaraldi, Giovanni, Borghi, V., Zona, Stefano, Ligabue, Guido, Busetti, G., Loria, Paola, Ballestri, Stefano, Losi, L., Nocetti, L., Schenetti, Luisa, and Mucci, Adele

Subjects
liver, NAFL, NASH, HR-MAS NMR, Magnetic resonance spectroscopy
Published
2010

114. Switching to boosted protease inhibitor plus a second antiretroviral drug (dual therapy) for treatment simplification: a multicenter analysis

Author

Zaccarelli, M, Fabbiani, Massimiliano, Pinnetti, C, Borghi, V, Giannetti, A, Sterrantino, G, Lorenzini, P, Latini, A, Loiacono, L, Colafigli, Manuela, Ammassari, A, D'Ettorre, G, Plazzi, M, Di Giambenedetto, Simona, Antinori, A., Di Giambenedetto, Simona (ORCID:0000-0001-6990-5076), Zaccarelli, M, Fabbiani, Massimiliano, Pinnetti, C, Borghi, V, Giannetti, A, Sterrantino, G, Lorenzini, P, Latini, A, Loiacono, L, Colafigli, Manuela, Ammassari, A, D'Ettorre, G, Plazzi, M, Di Giambenedetto, Simona, Antinori, A., and Di Giambenedetto, Simona (ORCID:0000-0001-6990-5076)

Abstract

To assess the role of drugs used in dual therapy (DT), as cART simplification, over the risk of treatment failure.

Published
2014

115. Incidence and risk factors of HIV-related non-Hodgkin's lymphoma in the era of combination antiretroviral therapy: a European multicohort study

Author

Collaboration of Observational HIV Epidemiological Research Europe Study Group, Bohlius, J, Schmidlin, K, Costagliola, D, Fätkenheuer, G, May, M, Caro Murillo AM, Mocroft, A, Bonnet, F, Clifford, G, Karafoulidou, A, Miro, Jm, Lundgren, J, Chene, G, Collaborators: Antinori A, Egger M., Boué, F, Brockmeyer, N, Casabona, J, Dronda, F, Obel, N, Fisher, M, Franceschi, S, Gibb, D, Le Moing, V, Nadal, D, Touloumi, G, Prins, M, Raffi, F, Roca, B, Verbon, A, Wolf, T, Fortuny, C, Chakraborty, R, Egger, M, Minder, C, Sterne, J, Zwahlen, M, Ellefson, M, Kjaer, J, Collin, F, Colin, C, Weller, I, Ledergerber, B, Warszawski, J, Meyer, L, Dabis, F, Krause, Mm, Goujard, C, Leport, C, de Wolf, F, Reiss, P, Porter, K, Dorrucci, M, Sabin, C, Del Amo, J, Thorne, C, Kirk, O, Staszewski, S, Perez Hoyos, S, Almeda, J, Antinori, A, Monforte, A, de Martino, M, Ramos, J, Battegay, M, Mussini, C, Tookey, P, Castagna, A, de Wit, S, Torti, Carlo, Teira, R, Garrido, M, Dedes, N, Phillips, A, Furrer, H, Newell, M, Telenti, A, Pantazis, N, Lechenadec, J, Jérôme, F, Tran, L, Balestre, E, Lanoy, E, Couturier, F, Rispens, T, Gras, La, Bhaskaran, K, Hill, T, Judd, A, Duong, T, Sobrino, P, Jennings, B, Pérez Hoyos, S, Bonfigli, S, Cozzi Lepri, A, Corvasce, S, Adorni, F, Ridolfo, Al, Paraninfo, G, Ramos, Jt, Keiser, O, Borghi, V, Masters, J, Ortiga, B, Salpietro, S, Rickenbach, M, Poll, B, and Garrido, M.

Published
2009

116. Patients presenting with AIDS in the HAART era: a collaborative cohort analysis

Author

Mussini, Cristina, Manzardo, C, Johnson, M, Monforte, A, Uberti Foppa, C, Antinori, A, Gill, Mj, Sighinolfi, L, Borghi, V, Lazzarin, A, Miró, Jm, Sabin, C, and Late Presenter Investigators

Subjects
Adult, Male, medicine.medical_specialty, Tuberculosis, Efavirenz, Immunology, HIV Infections, Cohort Studies, chemistry.chemical_compound, Acquired immunodeficiency syndrome (AIDS), Internal medicine, Antiretroviral Therapy, Highly Active, Drug Resistance, Viral, medicine, Immunology and Allergy, Humans, Survival rate, Retrospective Studies, AIDS-Related Opportunistic Infections, business.industry, Retrospective cohort study, Middle Aged, Viral Load, medicine.disease, Prognosis, CD4 Lymphocyte Count, Survival Rate, Regimen, Infectious Diseases, chemistry, HIV, AIDS, HAART, HIV-1, Female, Viral disease, business, Viral load
Abstract

Objective Many patients infected with HIV still present with an AIDS diagnosis. The aim of this study was to evaluate the virological, immunological and clinical outcomes of HAART in these patients. Design The present study was a multi-cohort study. All patients with an AIDS diagnosis between 30 days before and 14 days after HIV diagnosis, recruited between 1997 and 2004 from eight hospital cohorts, were evaluated. Results A total of 760 patients were included [268 (35.3%) had pneumocystis and 168 (22.1%) tuberculosis]. Six hundred and twenty-four patients (82.1%) started HAART a median of 31 days after HIV diagnosis. One hundred and fifty-three patients started a nonnucleoside transcriptase inhibitor-based regimen (20.1%), 409 a protease inhibitor-based regimen (53.8%) and 62 other regimens (8.2%). In adjusted analyses, HAART was started sooner in more recent years, in patients with lower CD4 cell count and in those with Kaposi's sarcoma, whereas it was started later in those with tuberculosis. Five hundred and five patients (89%) attained a viral load of less than 500 copies/ml. The factors associated with a better virological response were later calendar year, lower initial viral load and cytomegalovirus disease. Virological rebound was more common in those receiving nucleoside reverse transcriptase inhibitor-based regimens, in those with tuberculosis and in earlier calendar years. One hundred and twenty-five (16%) patients died; 61 had received HAART (48.6%). Mortality was more likely in those who were older, those with a higher viral load at diagnosis, those with nonsexual HIV risks and those with lower CD4 cell count and haemoglobin levels over follow-up. Conclusion Virological suppression was achieved in most AIDS patients, though mortality remains high in these individuals.

Published
2008

117. The governance of activation

Author

van Berkel, H.H.A., Borghi, V., Management of Meaning, and LSG Management of Meaning (MOM)

Subjects
International
Published
2008

119. Deregulation of CD95/CD95L system during acute HIV infection

Author

COSSARIZZA A, MUSSINI C, BORGHI V, MONGIARDO N, NUZZO C, PAGANELLI R, TRENTI T, ROSOK B, STENT G, NAGATA S, DE RIENZO B. AND FRANCESCHI C., GUIDO, Marcello, Cossarizza, A, Mussini, C, Borghi, V, Mongiardo, N, Nuzzo, C, Guido, Marcello, Paganelli, R, Trenti, T, Rosok, B, Stent, G, Nagata, S, and DE RIENZO, B. AND FRANCESCHI C.

Published
1997

124. Tenofovir treatment in HIV-related lipodystrophy syndrome. Retrospective observational forty-eight weeks follow-up study

Author

Guaraldi, Giovanni, Orlando, Gabriella, Roverato, A., DE SANTIS, Giorgio, Pedone, A., Spaggiari, A., Baccarani, A., De Fazio, D., Vandelli, M., Bertucelli, C., Beghetto, Barbara, Nardini, Giulia, Borghi, V., Grisendi, C., Bertolotti, Marco, Carubbi, Francesca, Zini, I., and Esposito, Roberto

Subjects
Lipodystrophy, Antiretroviral therapy, HIV, Lipodystrophy, liver disease, HIV, liver disease, Antiretroviral therapy
Published
2006

125. Virological response and resistance profile in HIV-1-infected patients starting darunavir-containing regimens.

Author

Armenia, D, Di Carlo, D, Maffongelli, G, Borghi, V, Alteri, C, Forbici, F, Bertoli, A, Gori, C, Giuliani, M, Nicastri, E, Zaccarelli, M, Pinnetti, C, Cicalini, S, D'Offizi, G, Ceccherini‐Silberstein, F, Mussini, C, Antinori, A, Andreoni, M, Perno, CF, and Santoro, MM

Subjects
HIV protease inhibitors, DRUG resistance in microorganisms, HIV infections, HIV-positive persons, SURVIVAL analysis (Biometry), TIME, VIRAL physiology, VIREMIA, DARUNAVIR, DESCRIPTIVE statistics, CD4 lymphocyte count, RITONAVIR, THERAPEUTICS
Abstract

Objectives We evaluated the virological response in patients starting a regimen based on darunavir/ritonavir ( DRV/r), which is currently the most widely used ritonavir-boosted protease inhibitor. Methods Data from 206 drug-naïve and 327 PI-experienced patients starting DRV/r 600/100 mg twice daily ( DRV600) or 800/100 mg once daily ( DRV800) were examined. The probabilities of virological success ( VS) and virological rebound ( VR) were evaluated in survival analyses. Baseline DRV/r resistance and its evolution at failure were also examined. Results DRV600 was preferentially administered in patients with complex requirements (older age, higher viraemia, lower CD4 cell count and DRV/ PI resistance) compared with DRV800. By 12 months, the probability of achieving VS was 93.2% and 84.3% in drug-naïve and PI-experienced patients, respectively. The higher the baseline viraemia, the longer was the time required to achieve VS, both in drug-naïve patients [>500 000 HIV-1 RNA copies/ mL: median [interquartile range ( IQR)] 6.1 (5.1-10.3) months; 100 000-500 000 copies/ mL: median ( IQR) 4.9 (3.8-6.1) months; <100 000 copies/ mL: median ( IQR) 3.9 (3.5-4.8) months; P < 0.001] and in PI-experienced patients [≥100 000 copies/ mL: median ( IQR) 7.2 (5.7-11.6) months; <100 000 copies/ mL: median ( IQR) 2.8 (2.4-3.3) months; P < 0.001]. In PI-experienced patients, the probability of VR was higher for higher viraemia levels (22.3% for ≥100 000 copies/ml vs. 9.7% for <100 000 copies/mL; P = 0.007). Baseline resistance did not affect the virological response. At failure, a high percentage of patients maintained virus susceptible to all PIs (drug-naïve: 95%; PI-experienced: 80%). Despite being used more often in patients with more complex requirements, DRV600 performed as well as DRV800. Conclusions In clinical practice, use of DRV/r (with its flexible dosage) results in high rates of virological response. These data support the use of PI/r in patients whose characteristics require potent drugs with a high genetic barrier. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

126. Comparison of three different interventions for the correction of HIV-associated facial lipoatrophy: a prospective study

Author

Guaraldi, G., Orlando, G., Fazio, D., Lorenzi, I., Rottino, A., Giorgio DE SANTIS, Pedone, A., Spaggiari, A., Baccarani, A., Borghi, V., and Esposito, R.

Subjects
Adult, Male, Injections, Intradermal, Polymers, Polyesters, Acrylic Resins, HIV Infections, Transplantation, Autologous, Humans, Pharmacology (medical), Lactic Acid, Prospective Studies, Pharmacology, HIV-Associated Lipodystrophy Syndrome, filler, Middle Aged, HIV infection, facial lipoatrophy, autologous fat transfer, Infectious Diseases, Treatment Outcome, Adipose Tissue, Tissue and Organ Harvesting, Female, Facial Dermatoses
Abstract

Objective To compare autologous fat transfer (AFT), injections of reabsorbable [polylactic acid (PLA)] and non-reabsorbable [polyacrylamide hydrogel (PAAG)] filler materials for the treatment of HIV-related facial lipoatrophy. Design and methods Eligible individuals with enough residual subcutaneous fat in the abdomen or in the dorso-cervical region were offered AFT surgery. Other individuals were blindly assigned to two different surgical teams, who administered a set of PLA or PAAG injections every 4 weeks. The primary endpoint was the measurement of Bichat's fat pad region, determined by the result of dermal plus subcutaneous thickness. Secondary endpoints included body image evaluation (determined by ABCD questionnaire), facial aesthetic satisfaction (determined by Visual Analogue Scale), and aesthetic pre- and post-picture comparisons by independent reviewers. All variables were measured at baseline and at 24 weeks after the last treatment session. Results Twenty-four individuals received AFT and 35 were selectively randomized to PLA (20) or PAAG (15) infiltrations. PLA and PAAG groups received a mean of 5 and 6 injections respectively ( P=NS). The mean change in dermal and subcutaneous thickness was 3.3 ±4.1 mm, 3.5 ±4.0 mm; 2.1 ±3.0 mm ( P=0.687), respectively. The mean change in ABCD score result was poorer in the AFT arm, but there were no other differences in other measured factors. Four serious adverse events were documented in the AFT arm only. Conclusions All three interventional techniques were highly effective in improving the aesthetic satisfaction of the patients. Longer follow-up is necessary to determine the most durable and suitable treatment.

Published
2005

135. CD4-Guided treatment interruptions: a new possibile therapeutic strategy

Author

Mussini, Cristina, Cozzi Lepri, A., Borghi, V., D’Arminio Monforte, A., De Luca, A., Sighinolfi, L., Ortolani, P., Barchi, E., Guaraldi, Giovanni, Bedini, A., Bratt, G., Erikson, L., Antinori, A., Cossarizza, Andrea, and Esposito, Roberto

Subjects
antiretroviral therapy, HIV, CD4 cell
Published
2003

136. Forme d ́uso del sapere esperto nell ́argomentazione delle scelte politiche

Author

Borghi, V, de Leonardis, O, Procacci, G, Polizzi, E, Mozzana, C, Borghi, V, de Leonardis, O, Procacci, G, Polizzi, E, and Mozzana, C

Abstract

In questo capitolo, viene messo sotto osservazione proprio il ruolo assunto dai saperi esperti e dalle argomentazioni presenti nelle politiche e nel dibattito su di esse in due campi specifici di politiche locali a Milano, come già specificato: la pianificazione urbana, con l’analisi del Documento di Piano di Governo del Territorio, adottato dalla Giunta Moratti nel 2010, e la programmazione delle politiche di salute mentale, con l’analisi del documento istitutivo del Tavolo per la prevenzione e sicurezza nell’area della Salute mentale, adottato nel 2009 dal Comune di Milano.

Published
2013

144. Prevalence of HIV-1 integrase mutations related to resistance to dolutegravir in raltegravir naïve and pretreated patients

Author

Saladini, F, Meini, G, Bianco, C, Monno, L, Punzi, G, Pecorari, M, Borghi, V, Di Pietro, M, Filice, G, Gismondo, Mr, Micheli, V, Penco, G, Carli, T, De Luca, Andrea, Zazzi, M., De Luca, Andrea (ORCID:0000-0002-8311-6935), Saladini, F, Meini, G, Bianco, C, Monno, L, Punzi, G, Pecorari, M, Borghi, V, Di Pietro, M, Filice, G, Gismondo, Mr, Micheli, V, Penco, G, Carli, T, De Luca, Andrea, Zazzi, M., and De Luca, Andrea (ORCID:0000-0002-8311-6935)

Abstract

The prevalence of HIV-1 integrase mutations related to resistance to the next-generation integrase inhibitor (INI), dolutegravir (DTG), was assessed in 440 INI-naïve subjects and in 120 patients failing a raltegravir (RTG)-containing regimen. Of the mutations selected by DTG in vitro, S153FY was not detected in any isolate while L101I and T124A were highly prevalent in both groups and significantly associated with non-B subtype. RTG-selected double and triple mutants, mostly the G140S/Q148H variant, were detected in only 32 (26.7%) RTG-treated patients. As L101I and T124A do not appear to exert any major effect in vivo and double and triple mutants resistant to DTG are infrequently selected by RTG, DTG can be effectively used in INI-naïve patients and may retain activity in many patients failing RTG.

Published
2012

145. The governance of activation

Author

Management of Meaning, LSG Management of Meaning (MOM), van Berkel, H.H.A., Borghi, V., Management of Meaning, LSG Management of Meaning (MOM), van Berkel, H.H.A., and Borghi, V.

Published
2008

146. Review article: the governance of activation

Author

Management of Meaning, LSG Management of Meaning (MOM), van Berkel, H.H.A., Borghi, V., Management of Meaning, LSG Management of Meaning (MOM), van Berkel, H.H.A., and Borghi, V.

Published
2008

148. Con-vivere nel conversare: vissuti e parole per una educazione alla politica

Author

Niccolai, G, Pedretti A.M, Borghi, V, Sangiovanni, B., Vitale, A, Barbolini, A., Formenti, L., Niccolai, Gianna, Pedretti, Anna Maria, Formenti, L, FORMENTI, LAURA, Niccolai, G, Pedretti A.M, Borghi, V, Sangiovanni, B., Vitale, A, Barbolini, A., Formenti, L., Niccolai, Gianna, Pedretti, Anna Maria, Formenti, L, and FORMENTI, LAURA

Abstract

Il testo è la post-fazione a una ricerca effettuata nella scuola, centrata sull'idea di insegnamento e apprendimento democratico; una ricerca-azione che ha visto coinvolti insegnanti e studenti di alcune scuole superiori del modenese. Questo capitolo introduce alcune riflessioni sul tema della con-versazione come metodo di ricerca ed educazione alla politica, quando riesce a creare attenzione, rigorosa e critica, per i vissuti e per le parole. Riformulare il senso della didattica come educazione è la sfida per la scuola di domani.

Published
2007

Catalog

Books, media, physical & digital resources
See catalog results